This company has been acquired
The company may no longer be operating, as it has been acquired. Find out why through their latest events.
KalVista Pharmaceuticals（KALV）株式概要
バイオ医薬品会社であるカルビスタ・ファーマシューティカルズ・インクは、アンメットニーズのある希少疾患の経口治療薬を開発している。 詳細
KALV Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
KalVista Pharmaceuticals, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$27.00 |
| 52週高値 | US$27.00 |
| 52週安値 | US$9.83 |
| ベータ | -0.11 |
| 1ヶ月の変化 | 0.75% |
| 3ヶ月変化 | 59.39% |
| 1年変化 | 108.33% |
| 3年間の変化 | 179.79% |
| 5年間の変化 | -3.67% |
| IPOからの変化 | 222.20% |
最新ニュース
Recent updates
Seeking Alpha • Apr 29
KalVista: 'Strong Buy' As Acquired By Chiesi And Positive KONFIDENT-KID Outcome
Summary KalVista Pharmaceuticals, Inc. is being acquired by Chiesi Group for $27/share in cash, valuing the company at $1.9 billion. KALV maintains a Strong Buy rating, driven by EKTERLY's $49.1M in 2025 sales and positive pediatric phase 3 KONFIDENT-KID interim results. EKTERLY is the first and only oral on-demand HAE therapy, with expansion into pediatric patients and multiple global markets underway. Key KALV risks include sNDA approval uncertainty for pediatric use, sustainability of EKTERLY sales, and successful Chiesi deal closure. Read the full article on Seeking Alpha
新しいナラティブ • Jan 23
Payer Restrictions And Slower Adoption Will Test Oral HAE Therapy But Long Term Potential Remains
Catalysts About KalVista Pharmaceuticals KalVista Pharmaceuticals develops oral therapies for hereditary angioedema, including EKTERLY for on demand treatment of HAE attacks. What are the underlying business or industry changes driving this perspective?分析記事 • Jan 10
Health Check: How Prudently Does KalVista Pharmaceuticals (NASDAQ:KALV) Use Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...分析記事 • Sep 05
Is KalVista Pharmaceuticals (NASDAQ:KALV) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...分析記事 • Jul 09
Here's Why We're Not Too Worried About KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...分析記事 • Apr 02
Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Seeking Alpha • Dec 18
KalVista: Potential First With Multiple Sebetralstat Regulatory Reviews In 2025
Summary NDA submission of sebetralstat was accepted for review by the FDA as an on-demand treatment option for HAE patients, with a PDUFA review date of June 17th of 2025. If sebetralstat is approved by the FDA, it would be the first and only on-demand oral treatment for HAE patients ages 12 and older. The global Hereditary Angioedema treatment market size is projected to reach $17.31 billion by the end of 2032. The company has an estimated pro forma cash balance of $292.2 million, which is expected to fund its operations into the 2H of 2027. Read the full article on Seeking AlphaSeeking Alpha • Nov 25
KalVista: Upcoming PDUFA, But Not Without Risks
Summary KalVista's lead candidate, sebetralstat, has shown strong phase 3 results for on-demand treatment of HAE, with a PDUFA date set for June 17, 2025. Sebetralstat offers rapid symptom relief for acute HAE attacks, differentiating it from long-acting treatments like Navenibart and prophylactic options like Berotralstat. Financial concerns include a limited cash runway of three quarters, necessitating potential dilution for commercialization efforts post-approval. Despite promising data, competition from gene therapies and the shift towards prophylactic treatments make me cautious about investing in KalVista now. Read the full article on Seeking Alpha分析記事 • Sep 12
Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Deliver On Growth Plans?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Seeking Alpha • Sep 05
KalVista Pharmaceuticals: Looking To Be A Major Player In HAE
Summary KalVista Pharmaceuticals, Inc. is advancing Sebetralstat, a potential first oral on-demand treatment for hereditary angioedema, with FDA approval expected in June 2025. Sebetralstat's successful Phase 3 trial and favorable safety profile position it to be a major player in the $900 million on-demand HAE market. Analysts are bullish on KalVista, with a recent Buy ratings and price targets ranging from $20 to $39 per share. KalVista has sufficient cash to fund operations into 2026, but may raise additional capital closer to the time around FDA approval. An analysis of KalVista Pharmaceuticals is presented in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Jun 24
Bullish On KalVista Pharmaceuticals: Sebetralstat Nears Approval, Aiming For 2025 Launch
Summary KalVista Pharmaceuticals develops oral small-molecule therapies for hereditary angioedema targeting plasma kallikrein and Factor XIIa. Sebetralstat completed Phase 3 trials and submitted an NDA in June 2024. The company targets 2025 US, EU, UK, and Japan launches. KalVista raised $150.1 million in February 2024, securing a cash runway approximately 2.2 years after the raise. Sebetralstat could capture the $900 million on-demand HAE market and enhance its TAM to the $2.9 billion HAE market. Despite recent equity dilution, I believe KalVista's financials and regulatory progress make it a "buy" for new investors aware of biotech risks. Read the full article on Seeking AlphaSeeking Alpha • Feb 14
KalVista: Positive Results From Phase 3 Trial Pave The Way For Commercialization (Downgrade)
Summary Sebetralstat has a compelling drug profile for the on-demand treatment of HAE attacks and could become the new standard of care in a billion-dollar market opportunity. KalVista is transitioning to a commercial company following positive Phase 3 data for sebetralstat, with potential approval in early 2025. The financing of the commercialization of sebestralstat is still unclear, but KalVista now has many options for business development without diluting shareholders too much. The oral Factor XIIa product candidate is another interesting compound in indications with high unmet medical need that will be moved into clinic in 2024. Read the full article on Seeking Alpha分析記事 • Jan 30
We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...分析記事 • Oct 04
We're Keeping An Eye On KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...分析記事 • May 02
We Think KalVista Pharmaceuticals (NASDAQ:KALV) Needs To Drive Business Growth Carefully
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Seeking Alpha • Oct 14
KalVista: Another Setback But The Key Value Driver Is Still In Place
Summary KalVista intends to provide best-in-class therapies, both for acute on-demand and prophylaxis treatment, to fundamentally change the way HAE is treated. Its lead drug Sebetralstat is currently being investigated in a Phase 3 study and top-line results are expected in the second half of 2023. Sebetralstat has a compelling drug profile for the on-demand treatment of HAE attacks and could become the new standard of care in a billion-dollar market opportunity. Although KalVista is funded beyond the next major milestones, the market does not attach value to the pipeline. KalVista once again shocks its shareholders with news regarding the termination of the KVD824 phase 2 trial. After its product candidate KVD001 failed to convince in a phase 2 study due to insufficient effectiveness a few years ago, safety concerns are the reason for the termination of the KVD824 trial. The news was very badly received by the market and, as a result, KalVista has lost more than 85% of its value since its peak following positive data on its product candidate Sebetralstat in 2021. Since Sebetralstat is apparently the main value driver of KalVista, and the developments in the pipeline do not allow any conclusions to be drawn about the latter, I wonder whether the high decline in the market capitalization of KalVista is justified. For me, the key value driver is still in place, meaning KalVista is significantly undervalued at current levels. In the following article, I want to introduce the company, explain my investment thesis and justify the potential of the value driver Sebetralstat. Business Of KalVista Pharmaceuticals KalVista (KALV) is a clinical-stage pharmaceutical company headquartered in Cambridge, Massachusetts, focused on developing oral therapies for the rare disease hereditary angioedema ((HAE)). KalVista intends to provide best-in-class therapies, both for acute on-demand and prophylaxis treatment, to fundamentally change the way HAE is treated. HAE is a rare and potentially life-threatening disease, and despite the fact that there are several approved therapies, there is a high unmet medical need to improve the quality of life and ease of disease control. KalVista went public in 2016 through a reverse merger with Carbylan Therapeutics and raised $78.2 million at $17 per share in its first public offering in 2018. The Pipeline Looks Bigger Than It Is The origin of KalVista's pipeline lies in the deep understanding of plasma kallikrein inhibitors. Prior to the change in strategy to focus on developing therapies for HAE, the molecules were also being investigated for diseases in diabetic macular edema ((DME)). In summary, however, KalVista's research efforts have not been very successful in the past. Investors should currently focus on KalVista's lead product candidate, Sebetralstat, formerly known as KVD900, which is currently being investigated in a placebo-controlled Phase 3 trial as an on-demand therapy for HAE attacks. The results of the study are expected to be published in the second half of 2023 which, if positive, will form the foundation for a regulatory submission in the first half of 2024. Since there is already very strong and meaningful data from the Phase 2 trial, I think it is very likely that the success can be duplicated in the Phase 3 trial. The Phase 2 study in 53 HAE patients demonstrated with statistical significance both the clinical efficacy across all primary and secondary endpoints and the overall safety profile of Sebetralstat. The factor XIIa program clearly has great potential, but is still in preclinical development and investors should not assign a value to it at this time. In 2023, KalVista plans to file an investigational new drug application ((IND)) to move the program into human clinical trials. The factor XIIa program has tremendous potential in the prophylactic treatment of HAE. It targets an enzyme that plays a key role in HAE and could block the underlying cause of HAE attacks. If successful in a proof-of-concept study, the program could be expanded in other large market opportunities in the area of inflammation and thrombosis. Overview of Kalvista's pipeline (Company Presentation) KVD824 was investigated in a Phase 2 study for the prophylactic treatment of HAE. However, KalVista has terminated the study due to safety concerns, which indicate that KVD824 will no longer meet the requirements for a best-in-class oral prophylactic therapy. In the beginning, the DME program with its product candidate KVD001 generated a great deal of interest and resulted in a collaboration with Merck (MRK). Following disappointing Phase 2 data in which the primary endpoint was missed, Merck did not extend the collaboration. However, as a dose-dependent clinical benefit on vision has been observed in certain patients, KalVista is still evaluating how to proceed with KVD001. Financial Situation Following the last capital raise following the publication of the Phase 2 data of Sebetralstat at a price of $36 per share, KalVista is currently in a good financial position. With $142 million in cash and a cash runaway until at least 2024, KalVista is funded across key milestones and significant value drivers. With the recently announced termination of the KVD824 Phase 2 trial, an additional $3 million in research and development costs can be saved on a quarterly basis. In my opinion, investors should not fear dilution, as current prices do not reflect the value of Sebetralstat in any way. Nevertheless, I would like to mention that KalVista has access to an ATM with Cantor Fitzgerald, and can issue shares in the amount of $100 million. However, I expect a funding effort with the publication of Phase 3 topline data in the second half of 2023. At current prices, KalVista has a negative pipeline value of approximately $18 million. Consequently, despite the good Phase 2 trial results and the independence to KVD824, investors do not believe that Sebetralstat will be successful. KalVista is currently very attractively valued (Author's Chart) Investment Thesis An investor should always be clear on the reasons for investing in a company. Therefore, I will present my reasons why I believe KalVista is an attractive investment at current prices. KalVista currently has a negative pipeline value even though its lead product candidate is being investigated in a Phase 3 trial in an attractive orphan indication with high unmet medical need. In my opinion, an investment in KalVista given a negative pipeline value is a good opportunity to speculate on a data run in the second half of 2023. The HAE market is very attractive and KalVista has the opportunity to take market share from the established players with a differentiated and more convenient mechanism of action. Personally, I expect KalVista to reach a positive pipeline value of at least $200 million before data readout, which equates to at least $10 per share. Although much higher prices are certainly possible with positive data, I would like to limit my investment thesis to the data run at this time and reduce risk prior to the data release. The release of the data represents a binary event and carries tremendous risk. Even though the peer comparison below does not allow a complete comparison, one can still conclude that KalVista is undervalued based on current share prices. BioCryst (BCRX), with its approved oral drug for the prophylactic treatment of HAE, is a good example of KalVista's potential pathway with positive data. Even Astria (ATXS), which still owes proof-of-concept, currently has a higher pipeline valuation than KalVista. However, it should be noted that Astria is about to publish Phase 2 data, while KalVista has no catalysts scheduled for the next 12 months. Comparison of companies with oral HAE therapies. (Author's Chart) Market Outlook In HAE And Potential of Sebetralstat Having made my investment thesis clear, I want to justify why I attribute substantial value to Sebetralstat. The current standard of care provides both on-demand and preventive treatments. Overall, 6000-8000 patients are affected in the US and up to 15,000 patients in Europe, which translates into up to 100,000 annual attacks in the US and 150,000 in Europe. According to forecasts, the HAE market will show tremendous growth in the coming years, reaching 4.5 billion in 2027. The market will focus more and more on the prophylactic treatment, nevertheless patients will always need a back-up solution in case of an attack. Global HAE Treatment Market is Substantial and Growing (Astria Company Presentation) Currently, there are a number of approved products for HAE patients. The largest player in the HAE market is Takeda (TAK) with its product Takhzyro, which is administered subcutaneously every two weeks for prophylactic treatment. For on-demand treatment of HAE, Takeda offers Firazyr and Kalbitor as subcutaneous injections, generating in total approximately 50% of sales in the HAE market. Overall, the HAE market is very competitive and new product candidates are attracting very high interest. For example, in 2015, Shire (now Takeda) bought Dyax and its product candidate Takhzyro for $5.9 billion after robust Phase 1b data. HAE is a Meaningful and Growing Global Market (Pharvaris Company Presentation) Despite the large number of approved therapies, the HAE market continues to have a high unmet medical need. Except for the oral prophyhlactic drug Orladeyo, all therapies are administered by injection, which is generally less convenient for patients and reduces patient compliance. Injections present a hurdle for patients because, despite their effectiveness, they can cause pain at the injection site, are time-consuming to administer, and are difficult to store. All approved on-demand options have significant shortcomings. Early treatment improves outcomes but undertreatment and late treatment are common. Source: KalVista The barrier of using injections is also shown by studies. These show that less than 40% of all treated attacks are dosed within the first hour, and up to 45% of attacks weren't treated at all. These numbers prove that patients want new medicines that deliver on all fronts. People Living with HAE Desire HAE Therapy that can Deliver on ALL Fronts (Pharvaris Company Presentation) KalVista believes that its oral product candidate, Sebetralstat, has the potential to change the treatment paradigm for this disease. People living with HAE actively seek new products that demonstrate improvements in efficacy, safety and tolerability, and convenience. In addition, research with patient physicians and payers indicate that the drug profile of Sebetralstat could meet these requirements in case of positive study results. As a result, 93% of all patients said they could imagine switching to the oral product candidate Sebetralstat if approved. The benefits of Sebetralstat arise mainly from the fact that the drug is taken earlier due to the lower barriers. Patients should take the drug at the first sign of symptoms. Combined with the rapid uptake of the drug, Sebetralstat has the potential to stop the development of an attack at an early stage while symptoms are still mild and swelling is not severe. Early treatment of attacks leads to better overall disease management and prevention of attacks reaching the critical stage of significant swelling and discomfort. We therefore believe that a safe, oral on-demand treatment has the potential to become a preferred alternative for patients currently using injectable treatments. Source: KalVista分析記事 • Sep 24
Here's Why We're Watching KalVista Pharmaceuticals' (NASDAQ:KALV) Cash Burn Situation
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Seeking Alpha • Sep 08
KalVista Pharmaceticals GAAP EPS of -$0.94
KalVista Pharmaceticals press release (NASDAQ:KALV): Q1 GAAP EPS of -$0.94. Cash, cash equivalents and marketable securities were $142.1 million as of July 31, 2022, compared to $166.2 million as of April 30, 2022. The decrease in the net cash and marketable securities position was due to cash consumption from operating expenses.Seeking Alpha • Aug 22
KalVista reaches five-month high as rival tumbles on hereditary angioedema
The shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) reached the highest level since March on Monday after Pharvaris N.V. (PHVS), its Dutch rival in hereditary angioedema (HAE), announced an FDA clinical hold on its lead asset, PHA121. An oral bradykinin B2-receptor antagonist, PHA121, is undergoing U.S. clinical studies in HAE under two Investigational New Drug (IND) applications for the rare inherited blood disorder. KalVista (KALV) is also advancing KVD900, its oral therapy for HAE, in a global late-stage trial with data expected in H2 2023. Even if PHVS resolves its clinical hold on its HAE candidate, the event will continue to be an overhang to a certain extent and “position KALV well if clinical data next year play out as we hope,” Stifel analyst Paul Matteis, who has a Buy rating and $32 on KALV wrote. Read: In April, Japanese pharma giant Takeda (TAK), a market leader in HAE, launched its Takhzyro injection for the condition in the U.S.Seeking Alpha • Jul 07
KalVista Pharmaceticals GAAP EPS of -$0.98 beats by $0.11
KalVista Pharmaceticals press release (NASDAQ:KALV): Q4 GAAP EPS of -$0.98 beats by $0.11. Cash, cash equivalents and marketable securities were $166.2M on April 30, 2022, compared to $248.9M on April 30, 2021. The decrease in the net cash position over the fiscal year is primarily due to increased operating expenses. “We are pleased with the progress we have made over the last fiscal year in the development of the candidates in our oral hereditary angioedema franchise,” said Andrew Crockett, Chief Executive Officer of KalVista. “We are meeting our enrollment targets for both our current clinical trials, the sebetralstat KONFIDENT Phase 3 and KVD824 KOMPLETE Phase 2. In addition, we are making great strides in developing our next wave of investigational compounds with promising preclinical data for our oral Factor XIIa inhibitor program. The Company is also well-capitalized, with funding until at least early 2024, which we expect takes us beyond data from both of our ongoing clinical trials.”分析記事 • May 18
Is KalVista Pharmaceuticals (NASDAQ:KALV) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...株主還元
| KALV | US Biotechs | US 市場 | |
|---|---|---|---|
| 7D | 0.2% | -4.4% | -0.2% |
| 1Y | 108.3% | 39.9% | 14.8% |
業界別リターン: KALV過去 1 年間で39.9 % の収益を上げたUS Biotechs業界を上回りました。
リターン対市場: KALV過去 1 年間で14.8 % の収益を上げたUS市場を上回りました。
価格変動
| KALV volatility | |
|---|---|
| KALV Average Weekly Movement | 12.8% |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.9% |
安定した株価: KALVの株価は、 US市場と比較して過去 3 か月間で変動しています。
時間の経過による変動: KALVの weekly volatility ( 13% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| n/a | 275 | Ben Palleiko | www.kalvista.com |
カルビスタ・ファーマシューティカルズ・インクはバイオ医薬品企業で、アンメットニーズのある希少疾患の経口治療薬を開発しています。同社の主要製品候補は、遺伝性血管性浮腫（HAE）の急性発作を治療する即効性の強力な血漿カリクレイン阻害剤であるエクテリー（EKTERLY）である。また、小児用口腔内崩壊錠であるHAE治療薬KONFIDENT-KID、思春期および成人患者を対象としたセベトラルスタットおよびODT製剤を評価するためのKONFIDENT、KONFIDENT-Sも開発中である。本社はマサチューセッツ州フラミンガム。
KalVista Pharmaceuticals, Inc. 基礎のまとめ
| KALV 基礎統計学 | |
|---|---|
| 時価総額 | US$1.44b |
| 収益（TTM） | -US$135.94m |
| 売上高(TTM) | US$114.48m |
12.6x
P/Sレシオ-10.6x
PER（株価収益率KALV は割高か？
公正価値と評価分析を参照収益と収入
| KALV 損益計算書（TTM） | |
|---|---|
| 収益 | US$114.48m |
| 売上原価 | US$56.02m |
| 売上総利益 | US$58.47m |
| その他の費用 | US$194.40m |
| 収益 | -US$135.94m |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | -2.55 |
| グロス・マージン | 51.07% |
| 純利益率 | -118.74% |
| 有利子負債／自己資本比率 | -1,385.2% |
KALV の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/06/12 12:00 |
| 終値 | 2026/06/10 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した ご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
KalVista Pharmaceuticals, Inc. 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4
| アナリスト | 機関 |
|---|---|
| null null | BTIG |
| Maurice Raycroft | Jefferies LLC |
| Serge Belanger | Needham & Company |